HUP0301451A3 - Use of cgmp pde5 inhibitors for the preparation of pharmaceutical compositions treating peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies - Google Patents

Use of cgmp pde5 inhibitors for the preparation of pharmaceutical compositions treating peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies

Info

Publication number
HUP0301451A3
HUP0301451A3 HU0301451A HUP0301451A HUP0301451A3 HU P0301451 A3 HUP0301451 A3 HU P0301451A3 HU 0301451 A HU0301451 A HU 0301451A HU P0301451 A HUP0301451 A HU P0301451A HU P0301451 A3 HUP0301451 A3 HU P0301451A3
Authority
HU
Hungary
Prior art keywords
neuropathies
peripheral
preparation
pharmaceutical compositions
vascular diseases
Prior art date
Application number
HU0301451A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HUP0301451A2 publication Critical patent/HUP0301451A2/hu
Publication of HUP0301451A3 publication Critical patent/HUP0301451A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0301451A 2000-06-30 2001-06-29 Use of cgmp pde5 inhibitors for the preparation of pharmaceutical compositions treating peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies HUP0301451A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21506500P 2000-06-30 2000-06-30
US21902900P 2000-07-18 2000-07-18
PCT/US2001/041202 WO2002002118A1 (en) 2000-06-30 2001-06-29 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies

Publications (2)

Publication Number Publication Date
HUP0301451A2 HUP0301451A2 (hu) 2003-09-29
HUP0301451A3 true HUP0301451A3 (en) 2004-10-28

Family

ID=26909649

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301451A HUP0301451A3 (en) 2000-06-30 2001-06-29 Use of cgmp pde5 inhibitors for the preparation of pharmaceutical compositions treating peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies

Country Status (13)

Country Link
EP (1) EP1303279A1 (hu)
JP (1) JP2004511433A (hu)
KR (1) KR20030047907A (hu)
CN (1) CN1440287A (hu)
AU (1) AU2001279275A1 (hu)
BR (1) BR0112100A (hu)
CA (1) CA2414352A1 (hu)
HU (1) HUP0301451A3 (hu)
IL (1) IL153426A0 (hu)
MX (1) MXPA03000033A (hu)
NZ (1) NZ523108A (hu)
PL (1) PL365565A1 (hu)
WO (1) WO2002002118A1 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020588D0 (en) * 2000-08-21 2000-10-11 Pfizer Ltd Treatment of wounds
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
CA2519357A1 (en) * 2003-03-17 2004-09-30 Pfizer Products Inc. Treatment of type 1 diabetes with pde5 inhibitors
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
EP1838319B1 (en) * 2005-01-07 2018-03-07 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders

Also Published As

Publication number Publication date
JP2004511433A (ja) 2004-04-15
WO2002002118A1 (en) 2002-01-10
KR20030047907A (ko) 2003-06-18
AU2001279275A1 (en) 2002-01-14
BR0112100A (pt) 2003-05-20
MXPA03000033A (es) 2003-09-25
NZ523108A (en) 2005-04-29
HUP0301451A2 (hu) 2003-09-29
PL365565A1 (en) 2005-01-10
IL153426A0 (en) 2003-07-06
CA2414352A1 (en) 2002-01-10
CN1440287A (zh) 2003-09-03
EP1303279A1 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
HUP0400918A3 (en) Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases
IL157656A (en) Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
HUP0401192A3 (en) Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds
HUP0401984A3 (en) Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
MY143795A (en) Tetrahydropyridoindole derivatives
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
SI1487541T1 (sl) Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
EP1631297A4 (en) TREATMENT OF IMMUNOSTIC DISEASES WITH ACTIVE VITAMIN D COMPOUNDS ALONE OR IN COMBINATION WITH OTHER THERAPEUTICS
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU2002345255A1 (en) Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
HK1092693A1 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
HUP0303306A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0301451A3 (en) Use of cgmp pde5 inhibitors for the preparation of pharmaceutical compositions treating peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303910A3 (en) Use of kapp-opiate agonists for preparation of pharmaceutical composition for the treatment of bladder dieseases
ZA200400210B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
HUP0302535A3 (en) Peptide compounds, pharmaceutical compositions containing them and their use for treatment of no-mediated diseases
HUP0301915A3 (en) Use of sildenafil and other compounds with pde5 activity for the preparation of pharmaceutical composition treating premature ejaculation
WO2002076397A3 (en) Telomerase inhibitors and methods of their use

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees